China’s Nasal Spray Corona Vaccine in Phase I Trials
Multiple research organizations and pharmaceutical companies progressing with developing vaccine candidate against deadly Corona virus. All those vaccines as part of pre-clinical and various phases of clinical trials were administered to the experimental animals and humans through smarting parenteral route.
Amid hold on vaccine study by AstraZeneca and University of Oxford, the researchers of China at Xiamen University and Hong Kong University in collaboration with Beijing Wantai Biological Pharmacy Enterprise Co. working on the development of a vaccine against new SARS-CoV-2, which can be administered via Intra nasally. Such an attempt is to avoid painful effects of age -old injectable vaccines.
On September 9,2020 China approved human testing of this nasal spray vaccine as part of Phase I clinical trials. The rationale for this research is based on the established nasal spray vaccine indicated for Influenza, live attenuated (LAIV). In the hunt for development of Needle free vaccines, which conveniently replaces the intra-muscular /sub-cutaneous route of administration of conventional vaccines.
Knowing the fact of mode of transmission of Corona virus into the body, it was assumed that any vaccine which is administered through nasal route will be more effective against virus without harming much the body’s whole immune system.
As reported by Science and Technology Daily, Preclinical studies have resulted that the nasal vaccine can significantly reduce lung damage among mice and hamsters when challenged with the coronavirus.
The intranasal spray contains weakened flu virus that carries the genetic segments of the coronavirus’s spike protein. Administered through the nasal tract, it mimics the natural infection of respiratory viruses to stimulate the body’s immune response against the pathogen that cause Covid-19. – Science and Technology Daily
